SKIDA1 and acute lymphoblastic leukemia: Considering each subtype of leukemia, the most divergent performance was observed in T-ALL, in which SKIDA1 had the best estimates (AUC: 0.991; CI: 0.981–1.000), followed by LAMP5 (AUC: 0.716; CI: 0.570–0.861), and CSPG4 (AUC: 0.558; CI: 0.418–0.698).